gatifloxacin has been researched along with Bacterial Disease in 27 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to evaluate gatifloxacin in adults with acute uncomplicated bacterial rhinosinusitis." | 9.10 | Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin. ( Nicholson, SC; Pankey, GA; Poole, MD; Sher, LD; Von Seggern, K; Wikler, MA, 2002) |
| "A soft and biocompatible hydrogel exhibiting a higher loading and the sustained release of gatifloxacin (GFLX) was developed as the potential matrix to fabricate a therapeutic contact lens for curing bacterial keratitis." | 7.79 | Preparation and characterization of a hydrogel carrier to deliver gatifloxacin and its application as a therapeutic contact lens for bacterial keratitis therapy. ( Fu, Y; Huang, Y; Lu, Q; Lv, H; Ma, D; Shi, Y; Xue, W; Zhong, J, 2013) |
| "The efficacy and safety of two oral dosing regimens of gatifloxacin were compared to ciprofloxacin in the treatment of complicated urinary tract infection in a randomised, double-blind multi-centre trial." | 6.71 | Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. ( Ankel-Fuchs, D; Bartnicki, A; Bischoff, W; Hanus, M; Milutinovic, S; Naber, KG; Schönwald, S; van Belle, F; Weitz, P, 2004) |
| "The efficacy and safety of two oral dosing regimens of gatifloxacin compared with ciprofloxacin for the treatment of acute uncomplicated lower urinary tract infection was investigated in a double-blind, randomised study, in adult female patients who received either gatifloxacin (400 mg as a single shot or 3 days of 200 mg once daily) or ciprofloxacin (250 mg given twice daily for 3 days)." | 6.71 | Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. ( Allin, DM; Ankel-Fuchs, D; Clarysse, L; Haworth, DA; Hopkins, G; James, IG; Naber, KG; Raini, C; Schneider, H; Wall, A; Weitz, P, 2004) |
| "Gatifloxacin (Tequin) is an 8-methoxy fluoroquinolone approved in the US for use in the treatment of community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute sinusitis, uncomplicated and complicated urinary tract infections (UTIs), pyelonephritis, gonorrhoea and uncomplicated skin and skin structure infections." | 6.43 | Gatifloxacin: a review of its use in the treatment of bacterial infections in the US. ( Croom, KF; Keam, SJ; Keating, GM, 2005) |
| "Gatifloxacin is an 8-methoxy fluoroquinolone antibacterial agent." | 6.41 | Gatifloxacin: a review of its use in the management of bacterial infections. ( Hurst, M; Onrust, SV; Ormrod, D; Perry, CM, 2002) |
| "We sought to evaluate gatifloxacin in adults with acute uncomplicated bacterial rhinosinusitis." | 5.10 | Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin. ( Nicholson, SC; Pankey, GA; Poole, MD; Sher, LD; Von Seggern, K; Wikler, MA, 2002) |
| "Topical fluoroquinolones, particularly besifloxacin, gatifloxacin, and moxifloxacin, have become important treatment options for common ocular bacterial infections due to their broad-spectrum bactericidal activity and low toxicity." | 4.88 | Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones. ( Bertino, JS; Jones, RN; Segreti, J, 2012) |
| "A soft and biocompatible hydrogel exhibiting a higher loading and the sustained release of gatifloxacin (GFLX) was developed as the potential matrix to fabricate a therapeutic contact lens for curing bacterial keratitis." | 3.79 | Preparation and characterization of a hydrogel carrier to deliver gatifloxacin and its application as a therapeutic contact lens for bacterial keratitis therapy. ( Fu, Y; Huang, Y; Lu, Q; Lv, H; Ma, D; Shi, Y; Xue, W; Zhong, J, 2013) |
| "The efficacy and safety of two oral dosing regimens of gatifloxacin were compared to ciprofloxacin in the treatment of complicated urinary tract infection in a randomised, double-blind multi-centre trial." | 2.71 | Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. ( Ankel-Fuchs, D; Bartnicki, A; Bischoff, W; Hanus, M; Milutinovic, S; Naber, KG; Schönwald, S; van Belle, F; Weitz, P, 2004) |
| "The efficacy and safety of two oral dosing regimens of gatifloxacin compared with ciprofloxacin for the treatment of acute uncomplicated lower urinary tract infection was investigated in a double-blind, randomised study, in adult female patients who received either gatifloxacin (400 mg as a single shot or 3 days of 200 mg once daily) or ciprofloxacin (250 mg given twice daily for 3 days)." | 2.71 | Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. ( Allin, DM; Ankel-Fuchs, D; Clarysse, L; Haworth, DA; Hopkins, G; James, IG; Naber, KG; Raini, C; Schneider, H; Wall, A; Weitz, P, 2004) |
| "Gatifloxacin (Tequin) is an 8-methoxy fluoroquinolone approved in the US for use in the treatment of community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute sinusitis, uncomplicated and complicated urinary tract infections (UTIs), pyelonephritis, gonorrhoea and uncomplicated skin and skin structure infections." | 2.43 | Gatifloxacin: a review of its use in the treatment of bacterial infections in the US. ( Croom, KF; Keam, SJ; Keating, GM, 2005) |
| "Gatifloxacin is a new 8-methoxy-fluoroquinolone antibiotic approved for use in the United States in December 1999." | 2.41 | Gatifloxacin, an advanced 8-methoxy fluoroquinolone. ( Fish, DN; North, DS, 2001) |
| "Gatifloxacin is a novel fluoroquinolone with a 3-methylpiperazine group at position 7 of the quinolone ring and a methoxy group at position 8 [287520,379131]; the 8-methoxy substituent seems to decrease the rate of development of resistance in Gram-positive bacteria [378631]." | 2.41 | Gatifloxacin Kyorin Pharmaceutical Co. ( Brown, WM, 2000) |
| "Gatifloxacin is an 8-methoxy fluoroquinolone antibacterial agent." | 2.41 | Gatifloxacin: a review of its use in the management of bacterial infections. ( Hurst, M; Onrust, SV; Ormrod, D; Perry, CM, 2002) |
| "Gatifloxacin is a novel extended-spectrum fluoroquinolone with improved gram-positive and anaerobe coverage compared with older agents such as ciprofloxacin." | 2.40 | Gatifloxacin. ( Barman Balfour, JA; Lamb, HM; Perry, CM, 1999) |
| "Gatifloxacin is a new 8-methoxy fluoroquinolone with enhanced activity against gram-positive cocci." | 1.31 | Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. ( Andes, D; Craig, WA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (22.22) | 18.2507 |
| 2000's | 17 (62.96) | 29.6817 |
| 2010's | 4 (14.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, Z | 1 |
| Lynch, AS | 1 |
| Zhang, J | 1 |
| Ba, Y | 1 |
| Wang, S | 1 |
| Yang, H | 1 |
| Hou, X | 1 |
| Xu, Z | 1 |
| Shi, Y | 1 |
| Lv, H | 1 |
| Fu, Y | 1 |
| Lu, Q | 1 |
| Zhong, J | 1 |
| Ma, D | 1 |
| Huang, Y | 1 |
| Xue, W | 1 |
| Segreti, J | 1 |
| Jones, RN | 2 |
| Bertino, JS | 1 |
| Menzies, DJ | 1 |
| Dorsainvil, PA | 1 |
| Cunha, BA | 1 |
| Johnson, DH | 1 |
| Sher, LD | 1 |
| Poole, MD | 1 |
| Von Seggern, K | 1 |
| Wikler, MA | 1 |
| Nicholson, SC | 1 |
| Pankey, GA | 1 |
| Matsuzaki, K | 1 |
| Watabe, E | 1 |
| Yoshimori, K | 1 |
| Shikano, M | 1 |
| Sato, Y | 1 |
| Hasegawa, M | 1 |
| Kobayashi, I | 1 |
| Solèr, M | 1 |
| Lode, H | 1 |
| Baldwin, R | 1 |
| Levine, JH | 1 |
| Schreurs, AJ | 1 |
| van Noord, JA | 1 |
| Maesen, FP | 1 |
| Zehrer, M | 1 |
| Naber, KG | 2 |
| Bartnicki, A | 1 |
| Bischoff, W | 1 |
| Hanus, M | 1 |
| Milutinovic, S | 1 |
| van Belle, F | 1 |
| Schönwald, S | 1 |
| Weitz, P | 2 |
| Ankel-Fuchs, D | 2 |
| Allin, DM | 1 |
| Clarysse, L | 1 |
| Haworth, DA | 1 |
| James, IG | 1 |
| Raini, C | 1 |
| Schneider, H | 1 |
| Wall, A | 1 |
| Hopkins, G | 1 |
| Mah, FS | 1 |
| Keam, SJ | 1 |
| Croom, KF | 1 |
| Keating, GM | 1 |
| Anon, JB | 1 |
| Fedler, KA | 1 |
| Sader, HS | 1 |
| Fritsche, TR | 1 |
| Kendall, C | 1 |
| Wooltorton, E | 1 |
| Catero, M | 1 |
| Ali, T | 1 |
| Greenfield, RA | 1 |
| Scofield, H | 1 |
| Bronze, MS | 1 |
| Wakabayashi, E | 1 |
| Mitsuhashi, S | 1 |
| Hosaka, M | 2 |
| Kinoshita, S | 1 |
| Toyama, A | 1 |
| Otsuki, M | 1 |
| Nishino, T | 1 |
| Kato, N | 1 |
| Kato, H | 1 |
| Tanaka-Bandoh, K | 1 |
| Watanabe, K | 1 |
| Ueno, K | 1 |
| Schaumann, R | 1 |
| Ackermann, G | 1 |
| Pless, B | 1 |
| Claros, MC | 1 |
| Rodloff, AC | 1 |
| Perry, CM | 2 |
| Barman Balfour, JA | 1 |
| Lamb, HM | 1 |
| Fish, DN | 1 |
| North, DS | 1 |
| Brown, WM | 1 |
| Ormrod, D | 1 |
| Hurst, M | 1 |
| Onrust, SV | 1 |
| Andes, D | 1 |
| Craig, WA | 1 |
| Yasue, T | 1 |
| Fukuda, H | 1 |
| Tomizawa, H | 1 |
| Aoyama, H | 1 |
| Hirai, K | 1 |
10 reviews available for gatifloxacin and Bacterial Disease
| Article | Year |
|---|---|
Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
Topics: Anti-Bacterial Agents; Bacterial Infections; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; | 2019 |
Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
Topics: Administration, Ophthalmic; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Bacteria; Bacte | 2012 |
Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections.
Topics: Administration, Topical; Aza Compounds; Bacterial Infections; Eye Infections; Fluoroquinolones; Gati | 2004 |
Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.
Topics: Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Humans; United Sta | 2005 |
Current management of acute bacterial rhinosinusitis and the role of moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Clinical Trials as Topic; Drug Resistanc | 2005 |
Dysglycemia and fluoroquinolones: are you putting patients at risk?
Topics: Adolescent; Adult; Aza Compounds; Bacterial Infections; Blood Glucose; Ciprofloxacin; Dose-Response | 2007 |
Gatifloxacin.
Topics: Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topic; Fluoroquinolones; Gatifloxaci | 1999 |
Gatifloxacin, an advanced 8-methoxy fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Gatifloxacin; Huma | 2001 |
Gatifloxacin Kyorin Pharmaceutical Co.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Clinical Trials as Topic; Contraindi | 2000 |
Gatifloxacin: a review of its use in the management of bacterial infections.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Drug Interactions; Drug Resistance, Microbial; | 2002 |
4 trials available for gatifloxacin and Bacterial Disease
| Article | Year |
|---|---|
Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin.
Topics: Acute Disease; Aged; Anti-Infective Agents; Bacterial Infections; Community-Acquired Infections; Dru | 2002 |
Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic Bronchitis.
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Bacteria | 2003 |
Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections.
Topics: Bacterial Infections; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2004 |
Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Double-Blind Me | 2004 |
13 other studies available for gatifloxacin and Bacterial Disease
| Article | Year |
|---|---|
Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Microbial Sensitivity | 2016 |
Preparation and characterization of a hydrogel carrier to deliver gatifloxacin and its application as a therapeutic contact lens for bacterial keratitis therapy.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Cell Line; Contact Lenses; Drug Carriers; Fluo | 2013 |
Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Blood Gl | 2002 |
[Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Cefdinir; Cephalosporins; Ciprof | 2002 |
Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003).
Topics: Adolescent; Adult; Aged; Aging; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Child; Child, | 2006 |
People with diabetes should avoid antibiotic gatifloxacin.
Topics: Bacterial Infections; Case-Control Studies; Contraindications; Diabetes Mellitus; Fluoroquinolones; | 2006 |
Gatifloxacin-associated hypoglycemia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Diabetes Mellitus, Type | 2007 |
In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; | 1994 |
Antibacterial properties of AM-1155, a new 8-methoxy quinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacteria, Anaerobic; Bacterial Infections; Culture Media; | 1995 |
Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria.
Topics: Animals; Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Cecum; Fluoroquinolones; | 1997 |
In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Gatifloxacin; Hu | 1999 |
Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Bacteria; Bacterial Infections; Dose-Response Rela | 2002 |
In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; DNA Topoisomerases, Type II; Dr | 1992 |